A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections
Christian Gege, Fernando Bravo, Nadja Uhlig, Timo Hagmaier, Rosanne Schmachtenberg, Julia Elis, Anke Burger‐Kentischer, Doris Finkelmeier, Klaus Hamprecht, Thomas Grünwald, David I. Bernstein, Gerald Kleymann
Abstract
-methylsulfon-imidoyl)thiazol-2-yl)acetamide} not only reduces the duration of disease symptoms or time to healing but also prevents recurrent disease in guinea pigs. Treatment of recurrent infections reduces the frequency of recurrences and viral shedding, and, unlike nucleosidic drugs, IM-250 remains effective for a time after cessation of treatment. Hence, IM-250 has advantages over standard-of-care therapies and represents a promising therapeutic for chronic HSV infection, including nucleoside-resistant HSV.
Topics & Concepts
Herpes simplex virusMedicineViremiaImmunologyGanciclovirVaricella zoster virusPopulationViral sheddingVirologyNucleoside analogueVirusHuman cytomegalovirusBiologyNucleosideBiochemistryEnvironmental healthHerpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchMosquito-borne diseases and control